Sae Im Jeong

Sae Im Jeong

Auto-generated profile, based on publicly available information

Sae Im Jeong

Department of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, Cheongju 28644, Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
JHJun Gi Hwang
Jun Gi Hwang
SJSae Im Jeong
Sae Im Jeong
YKYu Kyong Kim
Yu Kyong Kim
YLYujin Lee
Yujin Lee
SJSang Chun Ji
Sang Chun Ji
MPMin Kyu Park
Min Kyu Park
Hwang JG, et al. Transl Clin Pharmacol. 2022 Dec;30(4):212-225. https://doi.org/10.12793/tcp.2022.30.e23

15 April 2024 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
SJSae Im Jeong
Sae Im Jeong
MBMu Seong Ban
Mu Seong Ban
JHJun Gi Hwang
Jun Gi Hwang
MPMin Kyu Park
Min Kyu Park
SLSoo Lim
Soo Lim
JCJae-Yong Chung
Jae-Yong Chung
Aims: To explore the effect of renal function on the pharmacokinetic (PK) and pharmacodynamic (PD) profile and safety of enavogliflozin, a selective sodium‐glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes mellitus (T2DM). Methods: An open‐label, two‐part clinical trial was conducted in T2DM patients, stratified by renal function: Group 1, normal renal function; Group 2, mild renal impairment (RI); Group 3, moderate RI; and Group 4, severe RI. In Part A, Groups 2 and 4 received enavogliflozin 0.5 mg once. In Part B, Groups 1 and 3 received enavogliflozin 0.5 mg once daily for 7 days. Serial blood and timed urine samples were collected to analyse the PK and PD characteristics of enavogliflozin. Pearson's correlation coefficients were calculated to assess the correlations between PK or PD parameters and creatinine clearance (CrCL). Results: A total of 21 patients completed the study as planned. The area under the curve (AUC) for enavogliflozin was not significantly correlated with CrCL, although the maximum concentration slightly decreased as renal function decreased. By contrast, daily urinary glucose excretion (UGE) was positively correlated with CrCL after both single‐ ( r = 0.7866, p < 0.0001) and multiple‐dose administration ( r = 0.6606, p = 0.0438). Conclusions: Systemic exposure to oral enavogliflozin 0.5 mg was similar among the patients with T2DM regardless of their renal function levels. However, the glucosuric effect of enavogliflozin decreased with RI. Considering the UGE observed and approved therapeutic use of other SGLT2 inhibitors, the efficacy of enavogliflozin with regard to glycaemic control could be explored in patients with mild and moderate RI (estimated glomerular filtration rate ≥30 or ≥45 mL/min/1.73 m 2 ) in a subsequent larger study.

4 January 2023 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
SJSae Im Jeong
Sae Im Jeong
YKYun Kim
Yun Kim
JNJae Jin Nah
Jae Jin Nah
WHWan Huh
Wan Huh
IJIn‐Jin Jang
In‐Jin Jang
SLSeungHwan Lee
SeungHwan Lee

1 January 2022 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SJSae Im Jeong
Sae Im Jeong
HWHeejae Won
Heejae Won
ISIldae Song
Ildae Song
JOJaeseong Oh
Jaeseong Oh
Jeong SI, et al. Transl Clin Pharmacol. 2022 Jun;30(2):83-86. https://doi.org/10.12793/tcp.2022.30.e11

1 January 2024 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SPSe Rin Park
Se Rin Park
JHJun Gi Hwang
Jun Gi Hwang
SJSae Im Jeong
Sae Im Jeong
YCYoung-Sim Choi
Young-Sim Choi
HMHyo-Jin Min
Hyo-Jin Min
MPMin Kyu Park
Min Kyu Park
Park SR, et al. Transl Clin Pharmacol. 2024 Mar;32(1):63-72. https://doi.org/10.12793/tcp.2024.32.e6

1 January 2022 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
KHKi Young Huh
Ki Young Huh
SJSae Im Jeong
Sae Im Jeong
HYHyounggyoon Yoo
Hyounggyoon Yoo
MPMeihua Piao
Meihua Piao
HRHyeongju Ryu
Hyeongju Ryu
KKKyung Hwan Kim
Kyung Hwan Kim
Huh KY, et al. Transl Clin Pharmacol. 2022 Jun;30(2):87-98. https://doi.org/10.12793/tcp.2022.30.e7